HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulation/Legislation (Health)

Set Alert for Regulation {Health}

Regulation

Set Alert for Regulation {Health}

Latest From Health & Regulation

E-cigarette NRT Outlook Heated By Combining With Counseling, Nicotine-Tapering Strategy

Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.

OTC Drugs Research & Development

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.

Cannabidiol CBD International

US COVID-19 Fraud: Latest Chloride Dioxide Products Linked To Claims Are Oral Rinses

Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.

OTC Drugs Coronavirus COVID-19
See All

Legislation

Set Alert for Legislation {Health}

Latest From Health & Legislation

Senate Appropriators Press FDA On Acetaminophen Dosing, Pass On Expanding Drug Recall Authority

Senate Appropriations Committee has bills for federal agencies’ FY2021 budgets. The committee, which also published each subcommittee’s report accompanying its appropriation legislation, has not scheduled hearings to vote on the bills.

OTC Drugs Legislation

US Consumers 'May Already' See CBD As ‘Effective Therapeutic For Health Conditions’ – Study

Results of a JAMA study on why consumers say they use CBD supplements and an accompanying commentary emphasize that FDA should eliminate "unsupported claims of medical benefit” for CBDs and other cannabinoids.

Cannabidiol CBD OTC Drugs

Temporary Funding For US Agencies Delays $5M For FDA’s Cannabidiols Regulatory Pathway Work

Senate on 29 September was expected to a pass a CR the House passed a week earlier to fund FDA and other federal departments and agencies through 11 December.

Cannabidiol CBD Legislation
See All
UsernamePublicRestriction

Register